HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.

David BassanLeehee WeinbergerJason YiTanya KimMichael R WeistGregor B AdamsOrit FoordNeta ChaimSarit TabakNir BujanoverYael LopescoKristina VucciCaitlin SchnairLimor Levy-KnafoRichard L KendallFrank J CalzoneAdi Sharbi-Yunger

Published in: Journal for immunotherapy of cancer (2023)

We have preclinically validated an iCAR NOT gate technology broadly applicable for targeting HER2 expression in the context of A2 LOH. This approach is designed to prevent off tumor toxicity while allowing highly potent antitumor activity.

Keyphrases

induced apoptosis
oxidative stress
poor prognosis
cell cycle arrest
cancer therapy
drug delivery
binding protein
long non coding rna
anti inflammatory